Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    ...
    111
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA12 LOXOF G Levofloxacin (hemihydrate) - 500mg 500mg Tablet, film coated 141,103 L.L
M01AH05 COXIFLAM G Etoricoxib - 90mg 90mg Tablet, film coated 1,293,928 L.L
N02BE01 PARA-DENK 125 SUPPOS. G Paracetamol - 125mg 125mg Suppository 190,826 L.L
N05AE05 LAROZA G Lurasidone - 120mg 120mg Tablet, film coated 5,548,726 L.L
R03BA02 CORTAIR G Budesonide - 1mg/2ml 0.5mg/ml Inhalation suspension for nebuliser 1,209,458 L.L
A10BH01 SITAGLIPTINE ARROW G Sitagliptin - 100mg 100mg Tablet, coated 1,154,361 L.L
B01AF01 XAVIRAN G Rivaroxaban - 10mg 10mg Tablet, film coated 606,649 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 148,244 L.L
C03CA01 FUROSEMIDE RENAUDIN G Furosemide (sodium) - 20mg/2ml 20mg/2ml Injectable solution 451,531 L.L
C09CA03 ARBITEN 160 G Valsartan - 160mg 160mg Tablet 544,256 L.L
C10AA05 JOSWE ATORVAST 40 G Atorvastatin - 40mg 40mg Caplet, film coated 1,327,716 L.L
D08AX02 EOSIN ALCOHOLIC G Eosin - 1% 1% Solution 108,787 L.L
G04BE08 VIVIDA 5 G Tadalafil - 5mg 5mg Tablet, film coated 2,559,700 L.L
J01MA12 MATADOR G Levofloxacin - 500mg 500mg Tablet, film coated 787,492 L.L
M01AH05 ETOXA G Etoricoxib - 90mg 90mg Tablet, film coated 1,293,928 L.L
N02BE01 SULDEX 125 G Paracetamol - 125mg 125mg Suppository 110,067 L.L
N06AX26 LYTIOX G Vortioxetine - 10mg 10mg Tablet, film coated 2,064,142 L.L
R03BA02 BUDECORT G Budesonide - 1mg 1mg Respule 1,226,928 L.L
L02BX03 ABLAX 250 G Abiraterone acetate - 250mg 250mg Tablet L.L
A10BH01 SITAGLIPTINE ARROW G Sitagliptin - 50mg 50mg Tablet, coated 1,139,578 L.L
B01AF01 ZARLAN G Rivaroxaban - 10mg 10mg Tablet, film coated 1,439,255 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 159,736 L.L
C03CA01 FUROSEMIDE SALF G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 216,359 L.L
C09CA03 TABUVAN G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
C10AA05 LIPODAR G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 2,412,197 L.L
D08AX02 EOSIN AQUEUSE G Eosin - 1% 1% Solution 84,470 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 10mg 10mg Tablet 888,280 L.L
J01DC02 AXETINE G Cefuroxime sodium - 750mg 750mg Injectable powder for solution 1,193,332 L.L
J01MA12 OXALEV G Levofloxacin - 500mg 500mg Tablet, film coated 791,523 L.L
M01AH05 ETOXA G Etoricoxib - 90mg 90mg Tablet, film coated 431,309 L.L
    ...
    111
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025